darolutamide

Nubeqa® (Darolutamide) with ADT Achieved Better Overall Survival (OS) Than ADT Alone in Men with Non-Metastatic Castration-Resistant Prostate Cancer 

Nubeqa® (Darolutamide) with ADT Achieved Better Overall Survival (OS) Than ADT Alone in Men with Non-Metastatic Castration-Resistant Prostate Cancer 

Results from the final overall survival analysis of the Phase III ARAMIS Trial that investigated Nubeqa® (aka darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) show a significant improvement in their overall survival (OS) .